UPDATE: Benchmark Downgrades BioClinica to Hold Following Sale Agreement
January 31, 2013 at 07:31 AM EST
Benchmark downgraded BioClinica, Inc (NASDAQ: BIOC ) from Buy to Hold and maintained a $7.25 price target. Benchmark said, "BioClinica announced it has entered into a definitive agreement with the private equity firm, JLL Partners, to acquire BioClinica for $7.25 per share. This reflects 1.6x our forecast 2012
